• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.

作者信息

Sasaki Daichi, Hatakeyama Shingo, Tanaka Toshikazu, Okamoto Teppei, Yoneyama Takahiro, Ohyama Chikara

机构信息

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

出版信息

Int J Urol. 2022 Jul;29(7):772-773. doi: 10.1111/iju.14860. Epub 2022 Mar 13.

DOI:10.1111/iju.14860
PMID:35285092
Abstract
摘要

相似文献

1
Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.阿帕鲁胺治疗晚期前列腺癌时体型对皮肤相关不良事件的影响：一项多中心回顾性研究
Int J Urol. 2022 Jul;29(7):772-773. doi: 10.1111/iju.14860. Epub 2022 Mar 13.
2
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.在日本晚期前列腺癌患者中应用阿帕鲁胺后的皮疹：SPARTAN 和 TITAN 研究的 3 期综合分析和 1 期开放标签研究。
BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0.
3
Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.真实世界中美国接受阿帕鲁胺或恩扎卢胺治疗的非转移性去势抵抗性前列腺癌患者的不良事件负担。
BMC Cancer. 2022 Mar 22;22(1):304. doi: 10.1186/s12885-022-09364-z.
4
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.达罗他胺对比阿帕他胺和恩扎卢胺用于去势抵抗性前列腺癌的间接比较。
J Urol. 2021 Aug;206(2):298-307. doi: 10.1097/JU.0000000000001767. Epub 2021 Apr 5.
5
Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.体重过低是导致阿帕鲁胺相关皮肤不良事件的风险因素。
Anticancer Res. 2022 Apr;42(4):2023-2028. doi: 10.21873/anticanres.15682.
6
Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.在日本Chu-shikoku 日本泌尿科联盟的多机构研究中，对晚期前列腺癌日本患者中阿帕鲁胺相关皮肤不良事件的真实世界分析。
Int J Clin Oncol. 2022 Aug;27(8):1348-1355. doi: 10.1007/s10147-022-02183-z. Epub 2022 May 20.
7
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.阿帕鲁胺治疗与前列腺癌无转移生存。
N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
8
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.一项开放标签、I 期研究评估雄激素受体拮抗剂阿帕鲁胺在日本转移性去势抵抗性前列腺癌患者中的疗效。
Int J Clin Oncol. 2019 Dec;24(12):1596-1604. doi: 10.1007/s10147-019-01526-7. Epub 2019 Aug 24.
9
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.阿帕鲁胺对非转移性去势抵抗性前列腺癌患者健康相关生活质量的影响：SPARTAN 随机、安慰剂对照、3 期临床试验分析。
Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.
10
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.阿帕他胺治疗转移性去势敏感性前列腺癌（TITAN）患者的健康相关生活质量：一项随机、安慰剂对照、III 期研究。
Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29.

引用本文的文献

1
Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide.接受雄激素受体抑制剂阿帕鲁胺治疗的中国前列腺癌患者的皮肤不良事件
Front Immunol. 2025 Feb 20;16:1530919. doi: 10.3389/fimmu.2025.1530919. eCollection 2025.
2
Pharmacist Intervention in Outpatients With Prostate Cancer Prevents Apalutamide-induced Skin Adverse Events.药剂师对前列腺癌门诊患者的干预可预防阿帕鲁胺引起的皮肤不良事件。
In Vivo. 2025 Jan-Feb;39(1):459-466. doi: 10.21873/invivo.13849.
3
Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer.
中文：真实世界分析前列腺癌中国患者中阿帕鲁胺相关皮疹。
World J Urol. 2024 Mar 20;42(1):171. doi: 10.1007/s00345-024-04880-y.
4
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer.阿帕鲁胺与比卡鲁胺联合雄激素剥夺疗法用于治疗转移性激素敏感前列腺癌。
Sci Rep. 2024 Jan 6;14(1):705. doi: 10.1038/s41598-024-51389-w.
5
Apalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature.阿帕鲁胺诱发的毒性表皮坏死松解症在一名患有转移性去势敏感性前列腺癌的白种人患者中的病例报告及文献综述
Case Rep Oncol. 2023 Aug 16;16(1):652-661. doi: 10.1159/000532009. eCollection 2023 Jan-Dec.